What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
OCUL - Ocular Therapeutix, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$25.50
DETAILS
HIGH:
$30.00
LOW:
$21.00
MEDIAN:
$25.50
CONSENSUS:
$25.50
UPSIDE:
209.84%
Stock News
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Amy Ricca, the Company's new SVP, Head of HR. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.37 per share a year ago.
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027 HELIOS-3 Phase 3 trial in diabetic retinopathy ongoing Ocular to host Investor Day on Wednesday, June 17, 2026, in New York City, including key program and regulatory updates Cash balance of $666.7 million as of March 31, 2026, with expected runway into 2028 BEDFORD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data
Ocular Therapeutix (NASDAQ: OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Food and Drug Administration as it works toward a New Drug Application submission for AXPAXLI in wet age-related macular degeneration (wet AMD), with the company aiming to support approval based on its SOL-1
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R have an opportunity to enroll in the SOL-X trial for an additional three years SOL-X is designed to build on AXPAXLI's successful SOL-1 Phase 3 trial by exploring the potential to improve long-term visual outcomes with a dramatically reduced treatment burden BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been enrolled in the SOL-X long-term extension trial for AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026.
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC
Deltec Asset Management LLC cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ: OCUL) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,487,934 shares of the biopharmaceutical company's stock after selling 274,525 shares during
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in April 2026. Ocular plans to present additional data and analyses from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD).
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have issued a buy recommendation on
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
Adviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction value $71.01 million based on quarterly average price. The quarter-end value of position dropped by $65.05 million, reflecting both trading and Ocular Therapeutix share price changes.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to three newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fourteen research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to
Price Targets
RBC Capital on Ocular Therapeutix (OCUL): Weakness a Buying Opportunity
$30.00
(was $9.29)
Lisa Walter
·
RBC Capital
Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright
$21.00
(was $12.58)
H.C. Wainwright
Ocular Therapeutix price target raised to $19 from $15 at H.C. Wainwright
$19.00
(was $11.52)
H.C. Wainwright
Ocular Therapeutix price target raised to $31 from $21 at Piper Sandler
$31.00
(was $11.06)
Piper Sandler
Ocular Therapeutix price target raised to $24 from $17 at Baird
$24.00
(was $11.06)
Colleen Kusy
·
Robert W. Baird
Ocular Therapeutix price target raised to $29 from $20 at Citizens JMP
$29.00
(was $11.69)
Jonathan Wolleben
·
JMP Securities
Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness
$19.00
(was $6.50)
JMP Securities
Ocular Therapeutix price target lowered to $17 from $18 at Baird
$17.00
(was $8.37)
Colleen Kusy
·
Robert W. Baird
Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)
$15.00
(was $6.71)
Biren Amin
·
Piper Sandler
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
$14.00
(was $5.89)
Yi Chen
·
H.C. Wainwright
Ocular Therapeutix (OCUL) PT Raised to $24 at JMP Securities
$24.00
(was $9.29)
Jonathan Wolleben
·
JMP Securities
Ocular Therapeutix (OCUL) Stock Price: $10 Target And Overweight Rating
$10.00
(was $3.78)
Joseph Catanzaro
·
Piper Sandler